Companion diagnostics (CDx’s) are a group of clinical tests, emerging over the last decade, as an essential part of the concept of "personalized medicine". They allow clinicians to identify specific patients who are more likely to benefit from treatment with a particular drug or to estimate a patient’s prognosis. For example, in the field of clinical oncology, some clinical testing should be performed using molecular biology techniques (PCR, sequencing, bead-based assays, etc.) or pathological methods (IHC, FISH, CISH, etc.) to decide whether to use several novel medications against specific molecular targets.
MEBGEN™ RASKET KIT
MEBGEN™ RASKET KIT detects RAS (KRAS and NRAS) gene mutations rapidly and simultaneously in one well and in a single assay. It helps to predict the responce to anti-EGFR therapeutic antibodies (e.g. cetuximab and panitumumab) in colorectal cancer treatment, since mutations in RAS gene are associated with resistance to anti-EGFR therapeutic antibodies.
(EU only, not for USA)
Learn more >>